Amgen Inc Cash Flow Conversion Efficiency
Amgen Inc cash flow conversion efficiency. Based on the latest financial reports, Amgen Inc (AMGN) has a cash flow conversion efficiency ratio of 0.185x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Billion) by net assets ($8.66 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Amgen Inc (1988–2025)
Cash flow conversion efficiency of Amgen Inc from 1988 to 2025. This chart illustrates how Amgen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Amgen Inc (AMGN) share price today for real-time trading data and today's change.
Amgen Inc Cash Flow Conversion Ratio Explained
Amgen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Amgen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amgen Inc ranked by their cash flow conversion efficiency. Also see Amgen Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nestle S.A.
SW:NESN
|
0.181x |
|
BHP Group Ltd
AU:BHP
|
0.172x |
|
HERMES INTL UNSP.ADR 1/10
F:HMIA
|
N/A |
|
LOréal S.A.
PA:OR
|
0.113x |
|
McDonald’s Corporation
NYSE:MCD
|
-1.876x |
|
Shopify Inc
NYSE:SHOP
|
0.041x |
|
Commonwealth Bank of Australia
AU:CBA
|
-0.024x |
|
Abbott Laboratories
NYSE:ABT
|
0.054x |
Annual Cash Flow Conversion Efficiency for Amgen Inc (1988–2025)
The table below shows the annual cash flow conversion efficiency of Amgen Inc from 1988 to 2025. Review Amgen Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.66 Billion | $9.96 Billion | 1.150x | -41.17% |
| 2024-12-31 | $5.88 Billion | $11.49 Billion | 1.955x | +43.83% |
| 2023-12-31 | $6.23 Billion | $8.47 Billion | 1.359x | -48.81% |
| 2022-12-31 | $3.66 Billion | $9.72 Billion | 2.655x | +92.10% |
| 2021-12-31 | $6.70 Billion | $9.26 Billion | 1.382x | +23.90% |
| 2020-12-31 | $9.41 Billion | $10.50 Billion | 1.116x | +17.94% |
| 2019-12-31 | $9.67 Billion | $9.15 Billion | 0.946x | +4.68% |
| 2018-12-31 | $12.50 Billion | $11.30 Billion | 0.904x | +104.08% |
| 2017-12-31 | $25.24 Billion | $11.18 Billion | 0.443x | +27.77% |
| 2016-12-31 | $29.88 Billion | $10.35 Billion | 0.347x | +7.71% |
| 2015-12-31 | $28.21 Billion | $9.08 Billion | 0.322x | -3.05% |
| 2014-12-31 | $25.78 Billion | $8.55 Billion | 0.332x | +16.56% |
| 2013-12-31 | $22.10 Billion | $6.29 Billion | 0.285x | -7.74% |
| 2012-12-31 | $19.06 Billion | $5.88 Billion | 0.309x | +14.72% |
| 2011-12-31 | $19.03 Billion | $5.12 Billion | 0.269x | +11.30% |
| 2010-12-31 | $23.94 Billion | $5.79 Billion | 0.242x | -13.54% |
| 2009-12-31 | $22.67 Billion | $6.34 Billion | 0.280x | -4.84% |
| 2008-12-31 | $20.39 Billion | $5.99 Billion | 0.294x | -2.82% |
| 2007-12-31 | $17.87 Billion | $5.40 Billion | 0.302x | +6.36% |
| 2006-12-31 | $18.96 Billion | $5.39 Billion | 0.284x | +18.34% |
| 2005-12-31 | $20.45 Billion | $4.91 Billion | 0.240x | +27.99% |
| 2004-12-31 | $19.70 Billion | $3.70 Billion | 0.188x | +2.33% |
| 2003-12-31 | $19.45 Billion | $3.57 Billion | 0.183x | +49.09% |
| 2002-12-31 | $18.29 Billion | $2.25 Billion | 0.123x | -56.65% |
| 2001-12-31 | $5.22 Billion | $1.48 Billion | 0.284x | -25.11% |
| 2000-12-31 | $4.31 Billion | $1.63 Billion | 0.379x | +6.53% |
| 1999-12-31 | $3.02 Billion | $1.08 Billion | 0.356x | -12.51% |
| 1998-12-31 | $2.56 Billion | $1.04 Billion | 0.406x | -3.69% |
| 1997-12-31 | $2.14 Billion | $902.90 Million | 0.422x | -2.19% |
| 1996-12-31 | $1.91 Billion | $822.60 Million | 0.432x | -6.70% |
| 1995-12-31 | $1.67 Billion | $773.20 Million | 0.462x | +10.80% |
| 1994-12-31 | $1.27 Billion | $531.90 Million | 0.417x | +12.98% |
| 1993-12-31 | $1.17 Billion | $433.00 Million | 0.369x | +17.81% |
| 1992-12-31 | $933.70 Million | $292.80 Million | 0.314x | -24.19% |
| 1991-12-31 | $531.10 Million | $219.70 Million | 0.414x | +1119.56% |
| 1990-12-31 | $398.00 Million | $13.50 Million | 0.034x | -65.88% |
| 1989-12-31 | $188.10 Million | $18.70 Million | 0.099x | +372.80% |
| 1988-12-31 | $161.90 Million | $-5.90 Million | -0.036x | -- |
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more